Pfizer Inc. has agreed to allow other manufacturers to create its experimental COVID-19 pill, a move that may make the medicine available to more than half of the world’s population, according to the firm, which has signed an UN-backed agreement.

On Tuesday, Pfizer issued a statement announcing that it would license the antiviral pill to the Geneva-based Medicines Patent Pool, which would allow generic drug companies to produce the pill for use in 95 countries, which account for approximately 53 percent of the world’s population, according to the statement.

Pfizer Will Be Allowed To Produce Pfizer’s COVID-19 Drug Under License

The agreement excludes countries that have had devastating coronavirus outbreaks. Generally, a Brazilian pharmaceutical producer may make medicine for export, but the drug cannot be produced generically for domestic use in Brazil. Even though the deal was struck before Pfizer’s pill had been licensed in any country, experts think that the accord will help speed up the elimination of the pandemic.

Pfizer Will Be Allowed To Produce Pfizer's COVID-19 Drug Under License

In Esteban Burrone, the head of policy for the Medicines Patent Pool, we need to be able to provide 4 billion people access to a medication that seems to be effective and has just recently been developed. Even though he projected that other pharmaceutical firms would be able to start producing the pill within months, he realized that the arrangement would not be popular with everyone.

They are attempting to find a careful balance between the interests of the (business), the sustainability requirements of generic manufacturers, and the public health needs of low- and middle-income nations, according to Burrone. According to a stipulation of the deal signed by President Obama, Pfizer will not collect royalties on sales in low-income nations as long as COVID-19 is designated a public health emergency in the countries included by the pact.

Pfizer said earlier this month that its pill decreased hospitalization and death in those with mild to reasonable coronavirus infections by 90%. Independent specialists recommended that the research be discontinued because of the positive results of the company’s inquiry. For the sake of expediting the approval of the medicine, Pfizer has said that it would contact the US FDA and other regulatory bodies.

A medicine that can be taken at home and successfully relieve symptoms while also expediting recovery and keeping patients out of hospitals has been a top priority for scientists across the world since the COVID-19 pandemic broke out last year. COVID-19 treatments must be given intravenously or intramuscularly for the time being.

As of earlier this month, the COVID-19 pill created by Merck was authorized in the United Kingdom. A similar arrangement with the Medicines Patent Pool saw Merck agree to let other pharmaceutical companies make its COVID-19 medicine, molnupiravir, available in 105 poorer countries. Doctors voiced the disappointment without borders that China, Argentina, and Thailand were omitted from the Pfizer deal announced on Tuesday, despite its inability to serve everyone in the world.

Contrast this with other vaccine companies’ refusal to make vaccine formulations accessible for wider manufacturing, Pfizer and Merck’s decision on COVID-19 patent disclosure. As of yet, no pharmaceutical firm has shown interest in joining in a center the WHO built in South Africa to encourage the interchange of messenger RNA vaccine concepts and technology.